2024 ASCO Annual Meeting: GSK's belantamab mafodotin combo cuts multiple myeloma progression risk by 50% vs standard care, per DREAMM-8 phase III trial.

GSK's belantamab mafodotin, combined with pomalidomide and dexamethasone, improved outcomes for relapsed or refractory multiple myeloma patients versus standard care. The DREAMM-8 phase III trial showed a 50% risk reduction in disease progression or death. These positive results were presented at the 2024 ASCO Annual Meeting and published in the New England Journal of Medicine.